Avexxin AS, a Trondheim, Norway-based pharma company focusing on the development of novel small molecule therapeutics for patients suffering from chronic inflammatory conditions, closed a financing round of undisclosed amount.
The investment is led by Sarsia Seed, with participation from Leiv Eiriksson Invest.
The company intends to use the proceeds of the financing to develop its lead compound against psoriasis through clinical phase I/IIa
Founded in March 2005 as a result of years of scientific work at Prof. Berit Johansen’s laboratory at the Norwegian University of Science and Technology, and led by CEO Mikael Oerum, Avexxin also has early development programs targeting rheumatoid arthritis and glomerulonephritis.
Co-founders include Leiv Eiriksson Nyskaping and Ventac Partners, an international team with extensive experience in the management of life science companies.